Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00909428 · ClinicalTrials.gov registry record · Phase 4

Validation of a Real-time Urodynamic Measure of Urinary Urgency

A Phase 4 study, sponsored by Loyola University.

Completed
Registry status
Phase 4
Development phase
51
Enrollment target

NCT00909428: Completed Phase 4 study, sponsored by Loyola University.

NCT00909428 is a Phase 4 study that has completed, run by Loyola University. The registered enrollment target is 51 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00909428, a Phase 4 study, has completed, sponsored by Loyola University.

COMPLETED
Registry status
Phase 4
Development phase
51 participants
Enrollment target

Study Summary

Urinary urgency is a key symptom of overactive bladder syndrome (OAB) and may be more bothersome to a patient than the symptom of urinary frequency. Unfortunately, controversy continues to surround the term 'urgency' and there is no good tool to evaluate the severity of urgency. This fact has constrained the performance of clinical research in this field. The cause of urinary urgency is not fully understood and may vary from patient to patient. Although clinicians regularly obtain measures of bladder sensation during cystometry, little attention has been paid to the patient experience of urinary urgency. In this study, the researchers will use a non-significant risk device (i.e., an Urgeometer) to measure urinary urgency in women with overactive bladder.

Primary Outcome

At baseline, a small catheter is placed inside the participant's bladder. The bladder is filled with sterile water through the catheter and participants' maximal tolerated cystometric capacity (MCC) is measured in milliliters. Following completion of the bladder test, participants take 10mg solifenacin succinate (VesicareR) daily for 30 days. After 30 days of treatment, participants repeat the bladder test. Change in the MCC is used to evaluate the effectiveness of the drug.

Interventions

  • DRUG Solifenacin Succinate

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2007-01
Est. Completion 2009-02
Phase Phase 4
Loyola University

92 total trials

What the finished NCT00909428 record still lists

NCT00909428 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).

The record links to 0 conditions, and to 1 intervention - of which Solifenacin Succinate is the first listed.

NCT00909428 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00909428 about?

NCT00909428 is a clinical study titled "Validation of a Real-time Urodynamic Measure of Urinary Urgency". Urinary urgency is a key symptom of overactive bladder syndrome (OAB) and may be more bothersome to a patient than the symptom of urinary frequency. Unfortunately, controversy continues to surround the term 'urgency' and there is no good tool to evaluate the severity of urgency. This fact has constr...

What is the current status of trial NCT00909428?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2007-01. Estimated completion is 2009-02.

What interventions are being tested in trial NCT00909428?

The interventions under investigation include: Solifenacin Succinate (DRUG).

Who is sponsoring clinical trial NCT00909428?

This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00909428's enrollment target sits among peer trials

51 1249th of 2000 higher than 746 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02701153 · 51 participants · NA

    Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

  • NCT03663790 · 51 participants · NA

    Effects of Gait Retraining on Lower Extremity Biomechanics

  • NCT03874052 · 51 participants · Phase 1

    Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • NCT04704661 · 51 participants · Phase 1

    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00909428, the US trial registry maintained by the National Library of Medicine. NCT00909428 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.